London Daily

Focus on the big picture.
Thursday, Oct 02, 2025

Coronavirus FAQs: Can I Drink Between Vaccine Doses? What Is 'Vaccine Efficacy'?

Coronavirus FAQs: Can I Drink Between Vaccine Doses? What Is 'Vaccine Efficacy'?

People who've had dose 1 are wondering ... can I have a few drinks before dose 2 or will that muck things up? Also: Do you really understand the concept of "vaccine efficacy"? It's complicated!
I have started hearing that vaccine recipients should abstain from alcohol between the first and second doses of the COVID vaccine. Is this a thing?


It's true that chronic, heavy drinking and binge drinking can suppress your immune system, Kennedy says. And there are plenty of health reasons not to drink alcohol, he adds. But an occasional drink here and there — including a celebratory toast after your second shot? "That won't have an effect," he says.

What, exactly, does it mean that a vaccine is, for example, 92% efficacious? Does it mean there's an 8% chance of my getting COVID-19? If so, why would anyone want to get a vaccine that's only 60 or 65% efficacious?


I find the subject of vaccine efficacy very confusing!


Don't worry: If you find it confusing, you're probably on the right track! Efficacy rates (and effectiveness rates and point estimates and confidence intervals) should appear at least a little confusing to most non-biostatisticians. The concepts rely on statistical thinking that many aren't familiar with, says Brianne Barker, a virologist at Drew University.

The tendency to oversimplify has led many people to the same — mistaken — conclusion that an efficacy rate of 92 percent would mean that of 100 vaccinated people, 8 of them would get sick during a pandemic.

But that's not the case. Fortunately, a vaccine with a 92 percent efficacy rate actually means your chances of getting the disease is much, much less than 8 percent. It means that if you were exposed to the disease, your chances of getting infected would be 92 percent less if you were vaccinated than if you weren't.

If you want to geek out on the exact math on how much your chances of getting COVID drops after a vaccine, you'd have to know what the probability of getting sick is, Barker says. "And that varies based on the population that you look at."

Say you originally had a 10% chance of getting sick without being vaccinated. If you got that vaccine with an efficacy rate of 92%, your chance of getting sick would drop from 10% to less than 1% — 0.8%, to be exact.

In reality, the trials found that the probability of getting sick in the placebo groups was much less than 10%. In the Pfizer trial, for example, it was 0.79% — or less than one per 100 people. Participants who got the real vaccine had just a .04 percent chance of getting COVID ... that's 4 in 10,000 people.

While efficacy rates should, theoretically, make comparisons among different vaccines possible, a number of variables have made it more like "comparing an efficacy rate of 70 percent to purple," says Richard Kennedy, professor of medicine at the Mayo Clinic in Rochester, Minn., and co-director of the Vaccine Research Group.

"You're laughing because that's a ludicrous comparison," he says. But to truly make an apples-to-apples comparison, he says, you'd have to run the vaccines head-to-head in the same clinical trial. As it was, the characteristics of the participants in the various trials were different (Johnson & Johnson enrolled more people at higher risk, for example), variants were circulating during some trials and not others, and each trial defined the disease differently. (For example, Moderna defined a COVID-19 infection as a positive PCR test plus two symptoms from one group or one symptom from another group. Pfizer defined it as a positive PCR test plus one symptom.)

"The devil really is in the details," he says.

Can I get the Johnson & Johnson vaccine and then sign up for Pfizer or Moderna?


Theoretically, that should be fine, Barker and Kennedy agree. In real life, it's unlikely to happen — "it's hard enough to get one in the first place," Barker says, and "having already received one shot of Johnson & Johnson, you'd be considered fully vaccinated and probably no one is going to let you get another one because you're taking it away from someone who needs it," Kennedy says.

However, your body would likely handle the mixing and matching just fine, since all of the vaccines have the same antigen, Kennedy explains. The antigen is the component that your immune response recognizes — in this case, the spike protein. It's akin to the flu vaccine, he says. We get influenza vaccines every year, often with similar strains, without worrying about which company made it. When antigens are different, however, your body usually develops weaker antibodies.

"Another thing to consider is what will happen if we need booster doses in 6 months, 2 years, whenever," he says. "I doubt that we will have the resources or ability to only provide the same vaccine that you originally received."

And can people who have an allergic reaction to their first Pfizer or Moderna shot follow up with Johnson & Johnson?


Again, this may work in theory, Kennedy says, but until vaccines are more widely available it may not be possible. In the meantime, be reassured that your first dose may provide pretty good protection. After all, the Pfizer and Moderna vaccines weren't studied as single doses, so the efficacy rate after a month or two could be higher than you think, he points out.

Newsletter

Related Articles

0:00
0:00
Close
Trump Administration Launches “TrumpRx” Plan to Enable Direct Drug Sales at Deep Discounts
Trump Announces Intention to Impose 100 Percent Tariff on Foreign-Made Films
Altman Says GPT-5 Already Outpaces Him, Warns AI Could Automate 40% of Work
Singapore and Hong Kong Vie to Dominate Asia’s Rising Gold Trade
Trump Organization Teams with Saudi Developer on $1 Billion Trump Plaza in Jeddah
Manhattan Sees Surge in Office-to-Housing Conversions, Highest Since 2008
Switzerland and U.S. Issue Joint Assurance Against Currency Manipulation
Electronic Arts to Be Taken Private in Historic $55 Billion Buyout
Thomas Jacob Sanford Named as Suspect in Deadly Michigan Church Shooting and Arson
Russian Research Vessel 'Yantar' Tracked Mapping Europe’s Subsea Cables, Raising Security Alarms
New York Man Arrested After On-Air Confession to 2017 Parents’ Murders
U.S. Defense Chief Orders Sudden Summit of Hundreds of Generals and Admirals
Global Cruise Industry Posts Dramatic Comeback with 34.6 Million Passengers in 2024
Trump Claims FBI Planted 274 Agents at Capitol Riot, Citing Unverified Reports
India: Internet Suspended in Bareilly Amid Communal Clashes Between Muslims and Hindus
Supreme Court Extends Freeze on Nearly $5 Billion in U.S. Foreign Aid at Trump’s Request
Archaeologists Recover Statues and Temples from 2,000-Year-Old Sunken City off Alexandria
China Deploys 2,000 Workers to Spain to Build Major EV Battery Factory, Raising European Dependence
Speed Takes Over: How Drive-Through Coffee Chains Are Rewriting U.S. Coffee Culture
U.S. Demands Brussels Scrutinize Digital Rules to Prevent Bias Against American Tech
Ringo Starr Champions Enduring Beatles Legacy While Debuting Las Vegas Art Show
Private Equity’s Fundraising Surge Triggers Concern of European Market Shake-Out
Colombian President Petro Vows to Mobilize Volunteers for Gaza and Joins List of Fighters
FBI Removes Agents Who Kneeled at 2020 Protest, Citing Breach of Professional Conduct
Trump Alleges ‘Triple Sabotage’ at United Nations After Escalator and Teleprompter Failures
Shock in France: 5 Years in Prison for Former President Nicolas Sarkozy
Tokyo’s Jimbōchō Named World’s Coolest Neighbourhood for 2025
European Officials Fear Trump May Shift Blame for Ukraine War onto EU
BNP Paribas Abandons Ban on 'Controversial Weapons' Financing Amid Europe’s Defence Push
Typhoon Ragasa Leaves Trail of Destruction Across East Asia Before Making Landfall in China
The Personality Rights Challenge in India’s AI Era
Big Banks Rebuild in Hong Kong as Deal Volume Surges
Italy Considers Freezing Retirement Age at 67 to Avert Scheduled Hike
Italian City to Impose Tax on Visiting Dogs Starting in 2026
Arnault Denounces Proposed Wealth Tax as Threat to French Economy
Study Finds No Safe Level of Alcohol for Dementia Risk
Denmark Investigates Drone Incursion, Does Not Rule Out Russian Involvement
Lilly CEO Warns UK Is ‘Worst Country in Europe’ for Drug Prices, Pulls Back Investment
Nigel Farage Emerges as Central Force in British Politics with Reform UK Surge
Disney Reinstates ‘Jimmy Kimmel Live!’ after Six-Day Suspension over Charlie Kirk Comments
U.S. Prosecutors Move to Break Up Google’s Advertising Monopoly
Nvidia Pledges Up to $100 Billion Investment in OpenAI to Power Massive AI Data Center Build-Out
U.S. Signals ‘Large and Forceful’ Support for Argentina Amid Market Turmoil
Nvidia and Abu Dhabi’s TII Launch First AI-&-Robotics Lab in the Middle East
Vietnam Faces Up to $25 Billion Export Loss as U.S. Tariffs Bite
Europe Signals Stronger Support for Taiwan at Major Taipei Defence Show
Indonesia Court Upholds Military Law Amid Concerns Over Expanded Civilian Role
Larry Ellison, Michael Dell and Rupert Murdoch Join Trump-Backed Bid to Take Over TikTok
Trump and Musk Reunite Publicly for First Time Since Fallout at Kirk Memorial
Vietnam Closes 86 Million Untouched Bank Accounts Over Biometric ID Rules
×